European commission approves padcev™ (enfortumab vedotin) for locally advanced or metastatic urothelial cancer

- enfortumab vedotin is the first medicine approved in the eu for patients who received a prior platinum-containing chemotherapy and a pd-1/l1 inhibitor - tokyo and bothell, wash. , april 13, 2022 /prnewswire/ -- astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d.
SGEN Ratings Summary
SGEN Quant Ranking